A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis

BACKGROUND: Patients with idiopathic pulmonary fibrosis (IPF) often do not tolerate pirfenidone in the recommended dose of 2400 mg/day. The proportion of patients requiring dose reduction and its impact on survival in the real-world remain unclear. METHODS: Consecutive subjects with IPF were enrolle...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Sarcoidosis Vasc Diffuse Lung Dis
Main Authors: Dhooria, Sahajal, Agarwal, Ritesh, Sehgal, Inderpaul Singh, Prasad, Kuruswamy Thurai, Muth, Valliappan, Garg, Mandeep, Bal, Amanjit, Aggarwal, Ashutosh Nath, Behera, Digambar
Formato: Artigo
Idioma:Inglês
Publicado: Mattioli 1885 2020
Assuntos:
Original Article: Clinical Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7569556/
https://ncbi.nlm.nih.gov/pubmed/33093778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.36141/svdld.v37i2.8718
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares